Nadolol

證據等級: L5

預測適應症: 5 個

Nadolol: From Hypertension (Original Indication Undocumented) to Malignant Hypertensive Renal Disease

One-Sentence Summary

Nadolol (DB01203) is a non-selective beta-adrenergic blocker; no approved indication text is available in this evidence pack, and the drug is currently not marketed in Taiwan (0 licenses). The TxGNN model predicts it may be effective for Malignant Hypertensive Renal Disease, but this prediction is supported by 0 clinical trials and 0 publications — it rests entirely on the network prediction score.

Quick Overview

Item	Content
Original Indication	Not documented — no Taiwan license on file and `original_indications` is empty in this evidence pack
Predicted New Indication	Malignant Hypertensive Renal Disease
TxGNN Prediction Score	99.59%
Evidence Level	L5 (model prediction only, no trials or literature)
Taiwan Market Status	未上市 (Not marketed)
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not populated in drug.original_moa (flagged as a High-severity data gap, DG002). Based on the TxGNN-generated rationale accompanying this candidate, nadolol is described as a non-selective beta-adrenergic blocker that lowers systemic blood pressure by reducing cardiac output and suppressing renin secretion.

Malignant hypertensive renal disease is a hypertensive-emergency phenotype with acute renal injury. In principle, a systemic blood-pressure-lowering mechanism is directionally compatible with this condition’s treatment goal. However, the rationale itself flags an important fit-for-purpose mismatch: this clinical scenario typically requires titratable intravenous antihypertensives for rapid control, whereas nadolol is a long-acting oral agent (half-life 20–24 hours) — not a conventional treatment choice for an acute emergency. No clinical trial, trial registry, or publication record accompanies this candidate; the prediction is derived solely from the TxGNN network score (0.9959).

It is also worth noting that a tied-score sibling candidate (pulmonary hypertension owing to lung disease/hypoxia, rank 3) did return 20 PubMed records, but on review those papers concern hypoxia physiology, neurodegeneration, and tumor metabolism — none address nadolol or beta-blocker therapy in pulmonary hypertension. This illustrates a keyword-similarity artifact in the retrieval rather than genuine supporting evidence, and reinforces that the malignant-hypertensive-renal-disease candidate above should be read as an unvalidated network prediction only.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Taiwan Market Information

Nadolol currently holds no marketing license in Taiwan (0 licenses on record); no approved indication text, product name, or dosage form is available to report.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: No clinical trials or relevant literature support nadolol’s use in malignant hypertensive renal disease; the candidate is Evidence Level L5 (prediction-only). The drug is also unmarketed in Taiwan with no labeling/safety data on file (TFDA warnings/contraindications are a Blocking data gap, DG001), and the drug’s pharmacokinetic profile (long-acting oral) is a poor mechanistic fit for an acute hypertensive-emergency indication.

To proceed, the following is needed:

TFDA/international package insert with warnings and contraindications (resolves Blocking gap DG001)
Confirmed original indication and mechanism-of-action documentation (resolves High-severity gap DG002)
Preclinical or clinical evidence specific to malignant hypertensive renal disease (or its close variant, malignant renovascular hypertension)
Drug-drug interaction data, currently returned “not found”
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.